Acorda Therapeutics Inc. (ACOR) Sank To A 5-Month Low After Patient Deaths

Acorda Therapeutics Inc. (ACOR) announced Wednesday morning that it has halted new enrollment in two studies of tozadenant for Parkinson's disease following patient deaths.

from RTT - Before the Bell http://ift.tt/2ALLaUw
via IFTTT